FindTrial
Sign In

Treatment Response failure in Ovarian Cancer Patients

Molecular Characterization of Chemoresistance markers in Ovarian Cancer and its impact on Clinical Outcomes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/090058
Enrollment
42
Registered
2025-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Nitte University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed ovarian cancer patients above the age of 18 years 2. Ovarian cancer patients who will receive at least 3 cycles of platinum-based chemotherapy

Exclusion criteria

Exclusion criteria: 1. Patients with metastatic tumors originating from other primary sites 2. Patients with treatment history of platinum-based chemotherapy 3. Pregnant ovarian cancer patients 4. Patients with cognitive impairments and history of psychiatric illness

Design outcomes

Primary

MeasureTime frame
Clinical Outcomes such as Overall Survival, Progression Free Survival, Chemoresistance and Treatment ResponseTimepoint: Baseline, 9 Weeks (after 3rd Chemotherapy Cycle), 6 months—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Soumya Patil

NGSM Institute of Pharmaceutical Sciences

udayvenkatmateti@gmail.com9665137704

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026